Management ChangeJun 9, 2026, 06:16 AM
Lakefront Biotherapeutics Appoints Eric Hedrick as CMO
AI Summary
Lakefront Biotherapeutics announced the appointment of Eric Hedrick, MD, as its new Chief Medical Officer. This leadership expansion supports the company's strategic transformation following its recent acquisition of Ouro Medicines' operational assets. Dr. Hedrick brings 25 years of experience in developing effective and commercially successful therapies in the pharmaceutical and biotechnology industry.
Key Highlights
- Lakefront Biotherapeutics appointed Eric Hedrick, MD, as Chief Medical Officer.
- Dr. Hedrick will report to CEO Henry Gosebruch and join the Management Committee.
- The appointment supports the company's strategic transformation following the Ouro Medicines acquisition.
- Dr. Hedrick has 25 years of experience in pharmaceutical and biotechnology drug development.
- He previously served as clinical evaluation lead for new pipeline opportunities at Lakefront since July 2025.
- His prior roles include Chief Executive Physician at EQRx and CMO at Epizyme and Pharmacyclics.
Price Impact
More from GLPG